Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Cytosurge elects biotech leader Luba Greenwood to its Board, scaling its Same-Cell Biology platform to solve the causal data bottleneck in AI drug discover
-
MELBOURNE, Australia and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that its American Depositary Share (ADS) is expected to commence trading on the...
-
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well...
-
SAN CARLOS, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and...
-
Châtillon, France, le 17 juillet 2026 DBV Technologies dépose un prospectus relatif à son Programme At-The-Market (ATM) pour un montant pouvant atteindre 150 millions de dollars DBV Technologies...
-
Châtillon, France, July 17, 2026 DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market:...
-
Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenosertib SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL),...
-
WALTHAM, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in...
-
SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant...
-
EMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...